



# Kabra Drugs Limited

CIN NO : L02423MP1989PLC005438

Regd. Off : Shop No. 270, Shastri Market, Indore, Madhyapradesh. Phone : +91 98846 24100

To  
The Deputy Gen. Manager,  
Dept.of Corporate Services,  
BSE Ltd,  
P.J. Tower, Dalal Street,  
**Mumbai – 400 001.**

14 February 2024

**Subject: Undertaking for Non-Applicability of Regulation 32 of SEBI (LODR) Regulations, 2015 for the quarter ended 31<sup>st</sup> December 2023.**

As per Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the listed entity shall submit to the stock exchange the following statement(s) on a quarterly basis for public issue, rights issue, preferential issue etc.,-

- (a) Indicating deviations, if any, in the use of proceeds from the objects stated in the offer document or explanatory statement to the notice for the general meeting, as applicable;
- (b) Indicating category wise variation (capital expenditure, sales and marketing, working capital etc.) between projected utilization of funds made by it in its offer document or explanatory statement to the notice for the general meeting, as applicable and the actual utilization of funds.

In view of the aforesaid, I, the undersigned, Mr. KN Anand, Director of Kabra Drugs Limited hereby certify that Compliances of Regulation 32 of SEBI (LODR) Regulations, 2015 is not applicable to the company as the company has not issued any share by way of public issue, right issue, preferential issue etc. for the quarter ended 31st December 2023.

For Kabra Drugs Limited

**KN Anand**  
**Director**  
**DIN:03230186**

